# ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer

> **NCT05368506** · EARLY_PHASE1 · WITHDRAWN · sponsor: **OHSU Knight Cancer Institute**

## Conditions studied

- Advanced Fallopian Tube Carcinoma
- Advanced Ovarian Carcinoma
- Advanced Primary Peritoneal Carcinoma
- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Triple-Negative Breast Carcinoma
- Stage III Fallopian Tube Cancer AJCC v8
- Stage III Ovarian Cancer AJCC v8
- Stage III Primary Peritoneal Cancer AJCC v8
- Stage IV Fallopian Tube Cancer AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Stage IV Primary Peritoneal Cancer AJCC v8

## Interventions

- **DRUG:** Wee1 Inhibitor ZN-c3

## Key facts

- **NCT ID:** NCT05368506
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-07-30
- **Primary completion:** 2024-09-30
- **Final completion:** 2025-07-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI discretion
- **Last updated:** 2023-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05368506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05368506, "ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05368506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*